Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 5/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.38 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17054248 | 0.87 | MAPK14 (0.42) | KMT2A | |
| SCHEMBL19169550 | 0.84 | CNR2 (0.39) | CNR2KMT2AADORA3CYP19A1CYP1A1 | |
| SCHEMBL17055600 | 0.84 | APEX1 (0.49) | HRH3LMNACYP1A1CYP1A2CYP1B1 | |
| SCHEMBL17054245 | 0.84 | RARA (0.49) | KMT2ACYP1A1CYP1A2CYP1B1APEX1 | |
| SCHEMBL18557581 | 0.82 | TDO2 (0.39) | CNR2CYP19A1NPY5R | |
| SCHEMBL17054246 | 0.79 | RARA (0.40) | LMNACYP1A2APEX1 | |
| SCHEMBL9954348 | 0.76 | PTGS1 (0.49) | KDM1AKMT2AADORA3PTGS1PTGS2 | |
| SCHEMBL9510731 | 0.76 | NOTUM (0.54) | CNR2 | |
| SCHEMBL2091654 | 0.73 | KDM1A (0.48) | KDM1AKMT2AADORA3PTGS1PTGS2 | |
| SCHEMBL1458844 | 0.73 | ORAI1 (0.39) | APEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3110818-B1 | 9H-PYRIMIDO[4,5-B]INDOLES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS | UNIV MICHIGAN REGENTS (US) | 2019-10-23 | — | — | EP | disclosed |
| US-20170210761-A1 | 9H-PYRIMIDO [4,5-B]INDOLES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210761-A1 | 9H-PYRIMIDO [4,5-B]INDOLES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | CNR2 465/4885KDM1A 108/4885KMT2A 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.